Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Pharma giant Bristol-Myers Squibb is facing heat from hedge funds. Photo: Drew Angerer/Getty Images
Hedge funds Wellington Management and Starboard Value both oppose Bristol-Myers Squibb's $74 billion takeover of Celgene. Starboard said in an open letter Thursday that "other large, long-term shareholders" likewise believe it's a bad deal.
Why it matters: Bristol-Myers CEO Giovanni Caforio said in response that buying Celgene "is the best path forward for our company." But this mega-merger has a serious chance of failing if Bristol-Myers can't assuage investors' concerns about the "massive patent cliff" from Celgene's blockbuster drug Revlimid and the strength of its development pipeline.